Eli Lilly announces a $5.3 billion investment.
Funds allocated for the production growth of Zepbound and Mounjaro.
Expansion to enhance manufacturing capabilities.
Boosting supply to meet increasing demand for Zepbound.
Scaling up production to support global distribution.
The investment expected to create numerous jobs.